Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.42 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 2/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.39 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.38 |
| ▸ | TK2 | O00142 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL594248 | 0.94 | LMNA (0.46) | LMNASMN1; SMN2ADRB1DNMT1ALOX12 | |
| SCHEMBL594249 | 0.94 | LMNA (0.46) | LMNASMN1; SMN2ADRB1DNMT1ALOX12 | |
| Phosphoric Acid SCHEMBL595617 | 0.85 | TYMS (0.45) | LMNASMN1; SMN2ADRB1DNMT1TK1 | |
| SCHEMBL11915452 | 0.80 | ADRB1 (0.49) | LMNASMN1; SMN2ADRB1DNMT1ALOX12 | |
| SCHEMBL595058 | 0.80 | P2RY2 (0.47) | P2RY2POLBP2RY4 | |
| SCHEMBL594778 | 0.78 | ADK (0.45) | LMNASMN1; SMN2ADRB1DNMT1TK1 | |
| SCHEMBL594779 | 0.78 | ADK (0.45) | LMNASMN1; SMN2ADRB1DNMT1TK1 | |
| SCHEMBL12732344 | 0.78 | SLC29A1 (0.47) | LMNASMN1; SMN2ADRB1DNMT1ALOX12 | |
| SCHEMBL13030145 | 0.78 | SLC29A1 (0.47) | LMNASMN1; SMN2ADRB1DNMT1ALOX12 | |
| SCHEMBL2946371 | 0.78 | SLC29A1 (0.47) | LMNASMN1; SMN2ADRB1DNMT1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981078-B2 | Selective inhibitors of translesion DNA replication | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130004945-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | BERDIS ANTHONY J (US) | 2013-01-03 | — | — | US | disclosed |
| US-8114847-B2 | Selective inhibitors of translesion DNA replication | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090048202-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | CASE WESTERN RESERVE UNIVERSITY | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048202-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | REV1, PCNA, DNA2 | ADRB1 4674/4885ADRA1A 4752/4885LMNA 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.